Chemocentryx Stock News

ChemoCentryx, Inc. (CCXI) CEO Thomas Schall on Q4 2021 Results - Earnings Call Transcript

ChemoCentryx press release (CCXI): Q4 GAAP EPS of -$0.58 in-line.Revenue of $2.32M (-46.8% Y/Y) misses by $1.58M.Shares -14.6%.

-- Total revenue of $32.2 million in 2021 with $2.3 million in Q4; TAVNEOS ® (avacopan) US net product sales of approximately $1.0 million in Q4 2021 following US Food and Drug Administration (FDA) approval in ANCA-associated vasculitis -- -- TAVNEOS also approved in European Union (EU) triggering $45 million milestone from Vifor Pharma received in Q1 2022 --

ChemoCentryx (CCXI) delivered earnings and revenue surprises of -1.75% and 33.67%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

ChemoCentryx (NASDAQ:CCXI) is scheduled to announce Q4 earnings results on Tuesday, March 1st, after market close.The consensus EPS Estimate is -$0.55 (-27.9% Y/Y) and the consensus…

An investigation on behalf of current long term investors in ChemoCentryx, Inc. (NASDAQ:CCXI) shares over possible breaches of fiduciary duty by certain officers and directors was announced. San Diego, CA -- ( SBWIRE ) -- 02/24/2022 -- An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of ChemoCentryx, Inc. Investors who are current long term investors in ChemoCentryx, Inc. (NASDAQ: CCXI) shares, have certain options and should contact the Shareholders Foundation at [email protected] or call +1(858) 779 - 1554. The investigation by a law firm for investors in NASDAQ: CCXI stocks follows a lawsuit filed against ChemoCentryx, Inc. over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: CCXI stocks, concerns whether certain ChemoCentryx, Inc. directors are liable in connection with the allegations made in that lawsuit. The plaintiff alleges that the plaintiff claims that between November 26, 2019 and May 3, 2021, the defendants made false and/or misleading statements and/or failed to disclose that the study design of the Phase III ADVOCATE trial presented issues about the interpretability of the trial data to define a clinically meaningful benefit of avacopan and its role in the management of ANCA-associated vasculitis, that the data from the Phase III ADVOCATE trial raised serious safety concerns for avacopan, that these issues presented a substantial concern regarding the viability of ChemoCentryx''s NDA for avacopan for the treatment of ANCA-associated vasculitis, and that as a result of the foregoing, Defendants'' public statements were materially false and misleading at all relevant times.

MOUNTAIN VIEW, Calif., Feb. 23, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company''s fourth quarter and full year 2021 financial results will be released after market close on Tuesday, March 1, 2022. ChemoCentryx executive management will host a conference call and webcast beginning at 5:00 p.m. Eastern Time on March 1, 2022 to discuss these results and to answer questions.

MOUNTAIN VIEW, Calif., Feb. 23, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's fourth quarter and full year 2021 financial results will be released aft

SAN CARLOS, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 11 th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 16 th at 5:00 p.m. Eastern Time.

SAN CARLOS, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will participate in a fir

The stock price of ChemoCentryx, a biopharmaceuticals company focused on orally-administered therapeutics to treat autoimmune diseases and inflammatory disorders, has seen a fall of 30% over the last

Following approval in the EU, ChemoCentryx (CCXI) plans to launch Tavneos for treating ANCA-associated vasculitis in first-half 2022.

ChemoCentryx Inc (NASDAQ: CCXI ) shares are Full story available on Benzinga.com

The European Union has approved ChemoCentryx Inc''s (NASDAQ: CCXI ) Tavneos (avacopan) for ANCA-associated vasculitis. The approval follows the FDA approval of Tavneos in October 2021 . The approval covers the treatment combined with a rituximab or cyclophosphamide regimen for severe, active granulomatosis polyangiitis Full story available on Benzinga.com